Royalty Pharma plc and Ascendis Pharma A/S have announced a $150 million capped synthetic royalty funding agreement to support the U.S. commercial launch of Yorvipath, the first FDA-approved treatment for adult hypoparathyroidism. The partnership sees Ascendis receiving an upfront payment in exchange for a 3% royalty on U.S. net sales of Yorvipath, with a termination condition upon achieving a multiple of 2.0x or 1.65x by the end of 2029. Evercore and legal teams Latham & Watkins, Mazanti-Andersen, Goodwin Procter, and Fenwick & West advised the deal, which highlights Royalty Pharma’s commitment to innovative funding in biopharma and Ascendis’ strategic objectives to reduce capital costs while enhancing commercial flexibility.
Biopharmaceuticals, Private Equity,United States, Denmark
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement